Initial outcomes and safety of MR guided focused ultrasound (MRgFUS) thalamotomy for essential tremor of the first FUS Medical Unit in Portugal

• Tipo: Artigo em Revista Científica Internacional
• Data: 2024

Autores

Vila-Cha, N (Autor) Outra; Chamadoira, C (Autor) Outra; Araújo, R (Autor) FMUP; Oliveira, D (Autor) Outra; Costa, JA (Autor) Outra

Revista

Título: Arquivos de Neuro-Psiquiatria

Vol. 82

Páginas: 1-7

ISSN: 0004-282X

Editora: Associacao Arquivos de Neuro-Psiquiatria Dr. Oswaldo Lange

Indexação

ISI Web of Knowledge - 0 Citações

Scopus - 0 Citações

Outras Informações

ID Authenticus: P-016-XET

DOI: 10.1055/s-0044-1788668

Abstract (EN): Background The magnetic resonance imaging-guided focused ultrasound (MRgFUS) has emerged as an innovative treatment for patients with medically refractory essential tremor (ET). Objective This retrospective observational study aims to present the results of the first five patients with medically refractory ET who underwent MRgFUS treatment at this pioneering medical unit in Portugal. Methods We conducted a retrospective chart review for the first five patients who underwent unilateral MRgFUS thalamotomy of the ventral intermediate (Vim) nucleus to treat medically refractory ET at our medical unit. Results The mean patient age was 65.4 (26-84) years, and 60% were male. All patients had a family history of ET. The mean duration of disease was 17.4 years (range 10-24 years), and their dominant hand was the right. According to personal preference, the thalamotomy was performed on the left side in four patients, and on the right side in one. The MRgFUS thalamotomy led to significant improvements in both the clinical rating scale for tremor (CRST) score, by 62%, and the CRST composite score for the treated hand, by 73%. All patients experienced improvements in functionality and quality of life, by 52%. No severe adverse events were observed, and those that did occur during and following the procedure were mild and transient. Conclusion The initial results from Portugal's first MRgFUS medical unit indicate promising outcomes, with improvement in quality of life, as well as mild and temporary adverse events These findings contribute to the growing body of literature supporting the efficacy and safety of MRgFUS as a viable treatment option for patients with medication-resistant ET.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 7